晚期脊索瘤的药物治疗
脊索瘤是极罕见的骨肉瘤,可发生于脊柱和颅底。整块切除术是金标准,放疗有治愈和姑息获益。局部复发常见,高达40%患者发生远处转移,传统化疗不敏感,本综述聚焦晚期脊索瘤的药物治疗,包括传统化疗、分子靶向、免疫治疗及在研临床试验。
要点
- 脊索瘤极罕见,整块切除术是金标准,放疗可提供治愈和姑息获益。
- 即使完整手术切除后局部复发仍常见,高达40%患者发生远处转移。
- 传统细胞毒性化疗对脊索瘤不敏感,晚期患者需系统治疗,分子靶向和免疫治疗是新兴方向。
核心结论
- 本综述聚焦晚期脊索瘤的药物治疗,涵盖传统化疗、分子靶向药物、免疫治疗及在研临床试验和未来前景。
研究设计与样本
- 本综述为叙述性综述,聚焦晚期脊索瘤患者的药物治疗。
主要发现
- 脊索瘤是极罕见的骨肉瘤,可发生于脊柱任何部位和颅底。
- 整块切除术是治疗金标准,放疗已被证明可提供治愈和姑息获益。
- 即使完整手术切除后局部复发仍常见,高达40%患者发生远处转移,挽救治疗具有挑战性。
- 传统脊索瘤对细胞毒性化疗不敏感,而细胞毒性化疗被认为是转移性肉瘤患者的标准治疗选择。
- 过去十年引入了创新疗法,对疾病控制和患者生活质量产生积极影响;对脊索瘤分子特征的更好理解发现了新的潜在靶点。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chordoma is a very rare bone sarcoma that can arise from any site along the spine and from the skull base. En bloc resection is the gold standard for treatment while radiation therapy has been shown to provide both curative and palliative benefit. Unfortunately, local recurrences are common, even after a complete surgical resection, and up to 40% of patients suffer from distant metastases, while salvage treatments are challenging. Patients carrying an advanced disease need a systemic treatment. Unluckily, conventional chordoma are insensitive to cytotoxic chemotherapy that is considered the standard treatment option in patients with metastatic sarcoma. In the last decade, innovative therapies have been introduced, positively impacting disease control and patients' quality of life. In addition, a better understanding of the molecular characteristics of chordoma allowed to detect new potential targets. This review is focused on the pharmacological management of patients affected by an advanced disease, starting with a summary of data available on conventional chemotherapy, then moving to a deeper analysis of available data on molecular agents and immunotherapy, and finally providing an update on ongoing clinical trials and future prospective.
引用
- Colia V, Stacchiotti S. Medical treatment of advanced chordomas. Eur J Cancer. 2017. PMID: 28750274. doi:10.1016/j.ejca.2017.06.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。